Cellular distribution and cellular reactivity of platinum (II) complexes

Area of Science:

• Biochemistry
• Cancer Research
• Pharmacology

Background:

• Platinum-based chemotherapy is a cornerstone in cancer treatment.
• Understanding platinum complex mechanisms of action is crucial for drug development.
• Previous studies focused on total or DNA-bound platinum, but reactive platinum's role is less understood.

Purpose of the Study:

• To determine if cellular reactive platinum content predicts the growth inhibitory potential of platinum complexes.
• To compare the correlation between DNA-bound platinum, total cellular platinum, reactive platinum, and ED50 values.
• To investigate the cellular fate and storage of platinum complexes in cancer cells.

Main Methods:

• Human MCF-7 breast cancer cells were treated with cisplatin and platinum(II) complexes.
• Cellular platinum content was measured in total cells, nuclei, and chromosomal DNA using atomic absorption.
• Reactive platinum was quantified after reaction with added calf thymus DNA.
• Growth inhibitory potential was assessed by comparing platinum levels with ED50 values.

Main Results:

• DNA-bound platinum levels correlated with established ED50 values.
• Total cellular platinum, nuclear platinum, and reactive platinum showed no significant correlation with ED50 values.
• Differences in DNA platinum content were attributed to adduct formation rates rather than repair.
• Reactive platinum pools persisted in cells even after drug removal from the medium, indicating cellular storage.

Conclusions:

• Cellular reactive platinum content is not a reliable predictor of platinum drug efficacy.
• DNA adduct formation rate is a key determinant of platinum complex growth inhibition.
• Cancer cells may possess mechanisms for storing reactive platinum, influencing drug availability and prolonged effects.